Watson Pharmaceuticals, Inc.'s Eden Biodesign and Crucell N.V. Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6(R) Cell Line Technology

LIVERPOOL, United Kingdom & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Eden Biodesign Ltd. today announced the execution of a non-exclusive Vendor Network Agreement with Crucell, under which Eden Biodesign has become a pre-approved authorized provider of process development and cGMP manufacturing services using Crucell’s proprietary PER.C6® cell line technology. Under the terms of the agreement Eden Biodesign will be able to offer its services to Crucell’s PER.C6® licensees in the field of vaccines and gene therapy.